First National Trust Co. increased its holdings in Allergan PLC. (NYSE:AGN) by 10.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,361 shares of the company’s stock after buying an additional 218 shares during the period. First National Trust Co.’s holdings in Allergan PLC. were worth $574,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the stock. Honeywell International Inc. raised its stake in Allergan PLC. by 13.6% in the 2nd quarter. Honeywell International Inc. now owns 168,130 shares of the company’s stock valued at $40,871,000 after purchasing an additional 20,100 shares during the last quarter. Israel Discount Bank of New York acquired a new position in Allergan PLC. in the 1st quarter valued at about $988,000. Trust Co. of Vermont raised its stake in Allergan PLC. by 62.8% in the 1st quarter. Trust Co. of Vermont now owns 2,875 shares of the company’s stock valued at $687,000 after purchasing an additional 1,109 shares during the last quarter. Palladium Partners LLC raised its stake in Allergan PLC. by 1.7% in the 2nd quarter. Palladium Partners LLC now owns 31,161 shares of the company’s stock valued at $7,575,000 after purchasing an additional 523 shares during the last quarter. Finally, Capital Planning Advisors LLC raised its stake in Allergan PLC. by 79.3% in the 1st quarter. Capital Planning Advisors LLC now owns 3,674 shares of the company’s stock valued at $878,000 after purchasing an additional 1,625 shares during the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.
Allergan PLC. (AGN) opened at 231.21 on Wednesday. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80. The firm has a 50-day moving average price of $235.09 and a 200-day moving average price of $237.04. The stock has a market cap of $77.29 billion, a PE ratio of 7.04 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period last year, the business earned $3.35 EPS. The firm’s revenue was up 8.8% compared to the same quarter last year. Analysts forecast that Allergan PLC. will post $16.25 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s payout ratio is 9.95%.
Several research analysts recently weighed in on AGN shares. Sanford C. Bernstein reissued an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. ValuEngine downgraded shares of Allergan PLC. from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Cowen and Company set a $400.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Thursday, June 8th. Mizuho cut their target price on shares of Allergan PLC. from $275.00 to $267.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Finally, Royal Bank Of Canada set a $284.00 target price on shares of Allergan PLC. and gave the company a “buy” rating in a research note on Monday, June 12th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $274.69.
COPYRIGHT VIOLATION NOTICE: “First National Trust Co. Acquires 218 Shares of Allergan PLC. (AGN)” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/09/13/first-national-trust-co-acquires-218-shares-of-allergan-plc-agn.html.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.